158 related articles for article (PubMed ID: 17539051)
1. Trials and tribulations.
Nat Rev Drug Discov; 2007 May; 6(5):331. PubMed ID: 17539051
[No Abstract] [Full Text] [Related]
2. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
3. Food and Drug Administration requirements for approval of new anticancer drugs.
Johnson JR; Temple R
Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094
[TBL] [Abstract][Full Text] [Related]
4. Controversy trails adaptive clinical trials.
Goozner M
J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
[No Abstract] [Full Text] [Related]
5. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
[No Abstract] [Full Text] [Related]
6. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Forster MD; Saijo N; Seymour L; Calvert H
Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
8. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
9. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
[No Abstract] [Full Text] [Related]
10. Time to adapt.
Nature; 2010 Apr; 464(7293):1245-6. PubMed ID: 20428115
[No Abstract] [Full Text] [Related]
11. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
12. FDA launches "new use initiative".
Nat Biotechnol; 1997 May; 15(5):399. PubMed ID: 9131604
[No Abstract] [Full Text] [Related]
13. Unproven methods of cancer treatment: H.11.
CA Cancer J Clin; 1970; 20(3):172-5. PubMed ID: 4988623
[No Abstract] [Full Text] [Related]
14. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
[No Abstract] [Full Text] [Related]
15. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
16. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
17. Seamless Oncology-Drug Development.
Prowell TM; Theoret MR; Pazdur R
N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
[No Abstract] [Full Text] [Related]
18. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
19. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
20. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
